Leaders from HealthQuad, the largest healthtech venture capital fund in India, talk to In Vivo about why the country is a growing and promising market for digital investment.
There are more than 7,000 healthtech companies in India with total funding of around $4.7bn. Healthtech is predicted to become a $21bn market in the country by 2025.
HealthQuad is managing $100m across two active funds, HQ-I and HQ-II, with $185m deployed thus far. The VC is investing across the health care value chain, backing companies in:
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.
